IDEAYA Biosciences, Inc.
IDYA
Classificação em ações
#4744
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Preço da ação
$32.83
Última sincronização: 2026-10-16
Valor de mercado
$3.17B
Variação (1 dia)
-3.01%
Variação (1 ano)
12.20%
País
US
Negociar IDEAYA Biosciences, Inc. (IDYA)
Categoria
Healthcare
EPS de IDEAYA Biosciences, Inc. (IDYA)
EPS em June 2026 TTM: $-1.92
De acordo com os últimos relatórios financeiros e o preço das ações da IDEAYA Biosciences, Inc., o EPS atual da empresa (TTM) é $-1.92. No final de 2023, a empresa teve um EPS de $-1.96, um aumento em relação a ao EPS de 2022, que foi de $-1.42.
Histórico de EPS da IDEAYA Biosciences, Inc. de 2017 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.92 | -42.86% |
| 2024 | $-3.36 | 71.43% |
| 2023 | $-1.96 | 38.03% |
| 2022 | $-1.42 | 0.71% |
| 2021 | $-1.41 | 7.63% |
| 2020 | $-1.31 | -31.05% |
| 2019 | $-1.90 | -21.16% |
| 2018 | $-2.41 | 190.36% |
| 2017 | $-0.83 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,002.08% |
US
|
|
| $-7.98 | 315.63% |
US
|
|
| $-5.29 | 175.52% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,544.79% |
NL
|
